HemaCell
Suzhou
About HemaCell
Xueji Bio is a new cell therapy company founded by returnee experts to regenerate hematopoietic lineages (including blood cells and immune cells) in vitro, with unique stem cell reprogramming, editing and differentiation technologies. The company's unique iPSC establishment technology and gene targeting technology can quickly establish a platform using platelet cells as a drug delivery carrier.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $47.2M
- Funding stage: Early Stage Venture
- Last round: Series B (Dec 2025)
- Website: xuejibio.com
- Phone: 1-400-800-2526
Industries & Categories
Biotechnology, Pharmaceutical
Canonical: https://fsome.com/organization/hemacell-57765 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.